Quality of Life in HIV Positive Injecting Drug Users

  • M. Préau
  • A. D. Bouhnik
  • M. P. Carrieri
  • F. M. B. Spire
Reference work entry


The aim of this chapter is to present the research carried out to date worldwide on the quality of life of individuals HIV-infected through drug injection and more precisely to list factors associated with having higher quality of life scores. Before presenting factors explaining the impairment of quality of life, the first question to be approached is how to measure the quality of life of HIV patients infected through injecting drug use?

Firstly, vulnerabilities related to the medical characteristics of the follow-up of this population are investigated. These include access to treatment, co-morbidities and immuno-virological characteristics or side-effects of treatment. Psychosocial characteristics are also examined including the various kinds of social support available as well as several types of negative life events – for example those related to financial difficulties or violence. Finally, patterns of drug use and treatment for opiate dependence are considered in order to understand their impact on quality of life. Quality of life and its relationship with mental health are also examined due to their reciprocal impact on the clinical progression of HIV infection.

In conclusion, the quality of life of HIV patients infected through injecting drug use seems to be determined by a range of factors related to all aspects of these individuals’ lives. It is necessary to introduce a more comprehensive notion of care in medical follow-up targeted at those patients who are seriously marked by their history of substance dependence, by their HIV disease and by their personal life experience.


Inject Drug User Negative Life Event Methadone Maintenance Treatment Psychosocial Characteristic Opiate Dependence 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

List of Abbreviations:


acquired immunodefiency syndrome


highly active antiretroviral therapies


hepatitis B virus


hepatitis C virus


human immunodeficiency virus


injecting drug users


injecting drug user quality of life scale


methadone maintenance treatment


medical outcomes study questionnaire


nottingham health profile


opiate substitution treatment


pegylé interferon


quality of life interview


Spielberger’s state-trait anger expression inventory-2


world health organization quality of life


  1. Ammassari A, et al. (2001). J Acquir Immune Defic Syndr. 28(5): 445–449.PubMedGoogle Scholar
  2. Bouhnik AD, et al. (2002). J Acquir Immune Defic Syndr. 31(Suppl 3): S149–S153.PubMedGoogle Scholar
  3. Bouhnik AD, et al. (2005). Antivir Ther. 10(1): 53–61.PubMedGoogle Scholar
  4. Breitbart W, et al. (1997). Pain. 72(1–2): 235–243.PubMedCrossRefGoogle Scholar
  5. Burgoyne R, Renwick R. (2004). Soc Sci Med. 58(7): 1353–1366.PubMedCrossRefGoogle Scholar
  6. Burgoyne RW. (2005). AIDS Care. 17(1): 111–124.PubMedCrossRefGoogle Scholar
  7. Burgoyne RW, et al. (2004). AIDS Behav. 8(2): 151–163.PubMedCrossRefGoogle Scholar
  8. Carrieri MP, et al. (1999). J Epidemiol Commun Health. 53(1): 4–8.CrossRefGoogle Scholar
  9. Carrieri MP, et al. (2007). Int J Drug Policy. 18(4): 288–295.PubMedCrossRefGoogle Scholar
  10. Carrieri MP, Villes V, Raffi F, Protopopescu C, Préau M, Salmon D, et al. (2007). Int J Drug Policy. 18: 288–295.PubMedCrossRefGoogle Scholar
  11. Cascade T and Collaboration. (2000). Lancet. 355: 1158–1159.CrossRefGoogle Scholar
  12. Ciesla JA, Roberts JE. (2001). Am J Psychiatry. 158(5): 725–730.PubMedCrossRefGoogle Scholar
  13. Dalgard O, et al. (2004). Hepatology. 39(1): 74–80.PubMedCrossRefGoogle Scholar
  14. Donoghoe MC, et al. (2007). Int J Drug Policy. 18(4): 271–280.PubMedCrossRefGoogle Scholar
  15. Fleming CA, et al. (2004). Clin Infect Dis. 38(4): 572–578.PubMedCrossRefGoogle Scholar
  16. Gielen AC, et al. (2001). Soc Sci Med. 52(2): 315–322.PubMedCrossRefGoogle Scholar
  17. Grant I, et al. (1976). Arch Gen Psychiatry. 33(8): 973–978.PubMedGoogle Scholar
  18. Grella CE. (2003). J Psychoactive Drugs. 35(Suppl 1): 169–179.PubMedGoogle Scholar
  19. Hallinan R, et al. (2004). Aust N Z J Public Health. 28(6): 576–578.PubMedCrossRefGoogle Scholar
  20. Hubley AM, Russell LB, Palepu A. (2005). Health Qual Life Outcomes. 3: 43.PubMedCrossRefGoogle Scholar
  21. Jia H, et al. (2004). AIDS Patient Care STDS. 18(10): 594–603.PubMedCrossRefGoogle Scholar
  22. Kanwal F, et al. (2005). Am J Gastroenterol. 100(9): 1984–1994.PubMedCrossRefGoogle Scholar
  23. Knowlton A, Hua W, Latkin C. (2004). AIDS Behav. 8(4): 357–363.PubMedCrossRefGoogle Scholar
  24. Knowlton AR, Hua W, Latkin C. (2005). AIDS Care. 17(4): 479–492.PubMedCrossRefGoogle Scholar
  25. Larue F, Fontaine A, Colleau SM. (1997). Bmj. 314(7073): 23–28.PubMedGoogle Scholar
  26. Leserman J, et al. (2002). Psychol Med. 32(6): 1059–1073.PubMedCrossRefGoogle Scholar
  27. Litwin AH, Soloway I, Gourevitch MN. (2005). Clin Infect Dis. 40(Suppl 5): S339–S345.PubMedCrossRefGoogle Scholar
  28. Marimoutou C, et al. (2003). AIDS Care. 15(5): 729–734.PubMedCrossRefGoogle Scholar
  29. McDonnell KA, et al. (2005). Qual Life Res. 14(4): 945–957.PubMedCrossRefGoogle Scholar
  30. Metzger DS, Navaline H, Woody GE. (1998). Public Health Rep. 113(Suppl 1): 97–106.PubMedGoogle Scholar
  31. Mizuno Y, et al. (2003). AIDS Care. 15(5): 689–698.PubMedCrossRefGoogle Scholar
  32. Moore RD, Keruly JC, Chaisson RE. (2004). J Acquir Immune Defic Syndr. 35(1): 46–51.PubMedCrossRefGoogle Scholar
  33. Park-Wyllie LY, et al. (2007). AIDS Care. 19(2): 252–257.PubMedCrossRefGoogle Scholar
  34. Passik SD, et al. (2006). Clin J Pain. 22(2): 173–181.PubMedCrossRefGoogle Scholar
  35. Préau M, et al. (2004). AIDS Care. 16(5): 649–661.PubMedCrossRefGoogle Scholar
  36. Préau M, et al. (2005). J Psychosom Res. 59(6): 407–413.PubMedCrossRefGoogle Scholar
  37. Préau M, et al. (2006). Encephale. 32(5 Pt 1): 713–719.PubMedCrossRefGoogle Scholar
  38. Préau M, et al. (2007a). Aids. 21(Suppl 1): S19–S27.PubMedCrossRefGoogle Scholar
  39. Préau M, et al. (2007b). Drug Alcohol Depend. 86(2–3): 175–182.PubMedCrossRefGoogle Scholar
  40. Préau M, et al. (2008). J Clin Gastroenterol. 42(1): 92–96.PubMedCrossRefGoogle Scholar
  41. Préau M, Bouhnik AD, Peretti-Watel P, Obadia Y, Spire B. (2008). AIDS Care. 20: 917–924.PubMedCrossRefGoogle Scholar
  42. Préau M, et al. (2007c) AIDS Care. 19(4): 449–458.PubMedCrossRefGoogle Scholar
  43. Protopopescu C, et al. (2007). Qual Life Res. 16(4): 577–591.PubMedCrossRefGoogle Scholar
  44. Puigdollers E, et al. (2004). Subst Use Misuse. 39(9): 1353–1368.PubMedCrossRefGoogle Scholar
  45. Rodriguez-Arenas MA, et al. (2006). AIDS Res Hum Retroviruses. 22(8): 715–723.PubMedCrossRefGoogle Scholar
  46. Rothman G, Anderson BJ, Stein MD. (2008). AIDS Behav. 12: 695–704.PubMedCrossRefGoogle Scholar
  47. Shor-Posner G, et al. (2000). J Subst Abuse. 11(4): 395–404.PubMedCrossRefGoogle Scholar
  48. Spire B, Lucas GM, Carrieri MP. (2007). Int J Drug Policy. 18(4): 262–270.PubMedCrossRefGoogle Scholar
  49. te Vaarwerk MJ, Gaal EA. (2001). Eur J Public Health. 11(1): 109–115.PubMedCrossRefGoogle Scholar
  50. Tostes MA, Chalub M, Botega NJ. (2004). AIDS Care. 16(2): 177–186.PubMedCrossRefGoogle Scholar
  51. Trepanier LL, et al. (2005). J Clin Exp Neuropsychol. 27(1): 1–15.PubMedCrossRefGoogle Scholar
  52. van Beek I. (2007). Int J Drug Policy. 18(4): 329–332.PubMedCrossRefGoogle Scholar
  53. Wasserman DA, et al. (2006). Psychol Addict Behav. 20(3): 316–321.PubMedCrossRefGoogle Scholar
  54. Weis N, et al. (2006). Clin Infect Dis. 42(10): 1481–1487.PubMedCrossRefGoogle Scholar
  55. White JM. (2004). Addict Behav. 29(7): 1311–1324.PubMedCrossRefGoogle Scholar
  56. Wood E, et al. (2005a). Aids. 19(8): 837–839.PubMedCrossRefGoogle Scholar
  57. Wood E, et al. (2005b). Subst Use Misuse. 40(8): 1153–1167.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media LLC 2010

Authors and Affiliations

  • M. Préau
    • 1
  • A. D. Bouhnik
    • 1
  • M. P. Carrieri
    • 1
  • F. M. B. Spire
    • 1
  1. 1.Southeastern Health Regional Observatory (ORS-PACA)MarseilleFrance

Personalised recommendations